Seeing Is Believing
Currently out of the existing stock ratings of Kumaraguru Raja, 14 are a BUY (100%).
Analyst Kumaraguru Raja, currently employed at BROOKLINE, carries an average stock price target met ratio of 26.19% that have a potential upside of 38.32% achieved within 115 days.
Kumaraguru Raja’s has documented 24 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CYCC, Cyclacel Pharmaceuticals at 07-Mar-2023.
Analyst best performing recommendations are on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).
The best stock recommendation documented was for VERU (VERU) at 12/11/2020. The price target of $17 was fulfilled within 60 days with a profit of $10.64 (167.3%) receiving and performance score of 27.88.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$63
$43.37 (220.94%)
$63
2 days ago
(08-Nov-2024)
14/28 (50%)
$43.37 (220.94%)
165
Buy
$54
3 months 4 days ago
(06-Aug-2024)
3/5 (60%)
$21.39 (65.59%)
559
Buy
$86
$66.37 (338.10%)
$87
6 months ago
(10-May-2024)
1/3 (33.33%)
$58.74 (215.48%)
75
Buy
$48
$28.37 (144.52%)
$40
9 months 2 days ago
(08-Feb-2024)
4/8 (50%)
$10.09 (26.62%)
195
Buy
$36
1 years 3 months 27 days ago
(14-Jul-2023)
2/2 (100%)
$15.83 (78.48%)
271
What Year was the first public recommendation made by Kumaraguru Raja?